From September 29th to 30th, 2022, the 2-day 2022 (Second Edition) 3D Cell Culture and Organoid Symposium successfully concluded!
At this forum, bioGenous BIOTECH Inc. presented its full range of reagents, including normal tissue and tumor organoid culture kits, high-activity organoid culture growth factors, primary tissue storage solutions, and organoid cryopreservation solutions, as promised. The products received high praise from industry experts and participating clients! The company's organoid CRO, CDMO services, and organoid technical training services attracted numerous clients for consultation.
〢bioGenous Showcases Its All-Star Products
bioGenous shared with numerous professionals at the scene the company's original intention in developing standardized organoid culture kits and whole-process auxiliary reagents. This demonstrated bioGenous' fearless exploration in the field of organoids, attracting a large number of visitors to stop by and inspect the products, which were universally recognized by the audience.
〢High Popularity, Numerous Client Consultations
The booth was bustling with visitors, and the star products displayed on site attracted the attention of numerous clients.
Clients at the bioGenous booth communicated about product issues and shared resource information like long-lost friends. From time to time, passing clients praised bioGenous' research and development capabilities and its determination to drive industry development.
Since the launch of bioGenous "Let's Talk About Organoids" live stream every Thursday, the relaxed yet informative broadcast style has garnered a large following. At this exhibition, the two hosts of the live stream were also warmly engaging with visitors at the booth, with passing clients frequently asking, "Are you the teacher from the live stream?"
〢Walking Arm in Arm with Clients, Seeking Common Development
The bioGenous booth was extremely popular, with a steady stream of inquirers igniting the enthusiasm of the scene repeatedly. The staff were fully energized, using their utmost professional attitude to patiently and comprehensively answer each question posed by the inquirers. Regardless of whether a successful cooperation was achieved, they greeted everyone with smiles, treating everyone as guests, because we deeply understand that service and products are equally important.
〢Special Report: Discussing Organoid Technology and Scenario Standardization
The R&D Director of bioGenous was invited to deliver a special report titled "Standardization of Organoid Drug Development" at the forum on organoid technology and scenario standardization. For a replay of the report, please follow the "bioGenous WeChat Video Account" for viewing.
Professor ZHAO Bing, the Chief Scientist of bioGenous and a professor at Fudan University, was invited to deliver a special report titled "Advancing the Standardization of Organoid Technology through Multi-scenario Interdisciplinary Collaboration" at the forum on organoid technology and scenario standardization. For a replay of the report, please follow the "bioGenous WeChat Video Account" for viewing.
bioGenous BIOTECH Inc. is dedicated to providing standardized and modular organoid products and technical support for biomedical scientific research, drug development, and clinical precision medicine. Currently, it has served over 200 new drug development enterprises, tertiary hospitals, and scientific research institutions, offering users organoid automation equipment, whole-process reagent kits for multiple tissues, technical solutions for organoid culture and sample library construction, and subsystems for organoid drug development and precision medicine. With internationally leading organoid technology and independent intellectual property rights, bioGenous aims to become a unicorn enterprise in the upstream industry and lead the model revolution in multiple fields of biomedicine.
Tel : 400-600-8315
Web : www.biogenous.cn
E-mail : info@biogenous.cn
